Explore more publications!
Africa News Ledger
Got News to Share?

Africa News Ledger: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa News Ledger.

February 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28

March 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31

April 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30

Press releases published on April 6, 2026

Machine learning forecasts of child malnutrition integrated into Kenya’s drought early warning system for first time
Apr. 6, 2026

Machine learning forecasts of child malnutrition integrated into Kenya’s drought early warning system for first time

Indeterminate EIN Presswire
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
Apr. 6, 2026

Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement

Indeterminate GlobeNewswire
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
Apr. 6, 2026

Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM

Indeterminate GlobeNewswire
Avicanna Announces Changes to its Board of Directors
Apr. 6, 2026

Avicanna Announces Changes to its Board of Directors

Indeterminate GlobeNewswire
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
Apr. 6, 2026

Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain

Indeterminate GlobeNewswire
Neuronetics Announces Chief Financial Officer Transition
Apr. 6, 2026

Neuronetics Announces Chief Financial Officer Transition

Indeterminate GlobeNewswire
Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy
Apr. 6, 2026

Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy

Indeterminate GlobeNewswire
NoOnes Officially Releases SnapX Gift Card App
Apr. 6, 2026

NoOnes Officially Releases SnapX Gift Card App

Indeterminate EIN Presswire
XS.com Lança Programa de Fidelidade para Parceiros com Mais de $1M em Recompensas por Parceiro
Apr. 6, 2026

XS.com Lança Programa de Fidelidade para Parceiros com Mais de $1M em Recompensas por Parceiro

Indeterminate EIN Presswire
غرينبيس تنضم إلى "أسطول الصمود" 2026 لدعم مهمة إنسانية وكسر حصار غزة
Apr. 6, 2026

غرينبيس تنضم إلى "أسطول الصمود" 2026 لدعم مهمة إنسانية وكسر حصار غزة

Indeterminate EIN Presswire
Greenpeace MENA Joins the 2026 Global Sumud Flotilla to Support a Humanitarian Mission to Gaza
Apr. 6, 2026

Greenpeace MENA Joins the 2026 Global Sumud Flotilla to Support a Humanitarian Mission to Gaza

Indeterminate EIN Presswire
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Apr. 6, 2026

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Indeterminate GlobeNewswire
Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure
Apr. 6, 2026

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure

Indeterminate GlobeNewswire
Stablecoin Development Corporation Begins Trading on NYSE American Under Ticker “SDEV”
Apr. 6, 2026

Stablecoin Development Corporation Begins Trading on NYSE American Under Ticker “SDEV”

Indeterminate GlobeNewswire
Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors
Apr. 6, 2026

Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors

Indeterminate GlobeNewswire
Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor
Apr. 6, 2026

Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor

Indeterminate GlobeNewswire
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Apr. 6, 2026

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

Indeterminate GlobeNewswire
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
Apr. 6, 2026

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026

Indeterminate GlobeNewswire
DEEP SEA MINERALS CORP. APPOINTS FORMER DEPARTMENT OF ENERGY CFO, JOHN G. VONGLIS AS STRATEGIC ADVISOR
Apr. 6, 2026

DEEP SEA MINERALS CORP. APPOINTS FORMER DEPARTMENT OF ENERGY CFO, JOHN G. VONGLIS AS STRATEGIC ADVISOR

Indeterminate GlobeNewswire
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr. 6, 2026

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions